Mango Medical
We simulate orthopedic surgeries based on CT scans
Winter 2026ActiveHealthcareHealthcare ITRobotic SurgeryHealthcare ITAISan Francisco, CA, USA
Company
https://mangomedical.ioMango Medical builds agentic surgical planning AI for orthopedic surgery. We deliver surgeon-ready 3D plans in minutes instead of days. $10M ARR LOI from a top orthopedic company. Pursuing FDA 510(k) clearance. We're building a future where every surgery follows a personalized plan.
Verdict
High Signal
Market Opportunity
Orthopedic surgical planning is a large, well-defined B2B healthcare IT market — the global orthopedic surgical planning software market is multi-billion dollar with clear ICP (orthopedic surgeons, hospital systems, medical device companies). The $10M ARR LOI from a top orthopedic company suggests enterprise monetization path is real. FDA 510(k) clearance pursuit indicates a regulatory moat once achieved.
Medium Signal
Founder Signal
Adrian Kilian is a dentist (Kiel University, Zahnmedizin 2012-2019) turned CEO with 5+ years building Mango Medical — domain credibility but no prior tech or startup exits. Jorge Padilla Perez is CTO with an MS in Biomedical Computing from TU Munich and real AI/medical imaging work at University of Augsburg and AR research at TU Munich, but his senior role at Mango only started July 2023 and he has no prior industry exits or big-company engineering pedigree.
Medium Signal
Competition
No competitor data was returned in the research, but this space has established players including Materialise (surgical planning software), Stryker's planning tools, and Zimmer Biomet's digital surgery platforms, plus AI startups like Imagen Technologies. The proprietary CT-scan-to-3D-plan AI pipeline and potential FDA clearance could differentiate meaningfully, but the competitive moat is unproven without more product detail.
Medium Signal
Product
They claim a $10M ARR LOI from a top orthopedic company and are pursuing FDA 510(k) clearance — strong commercial signal if real, but it's an LOI not actual revenue. The website is essentially a contact form with no live demo, no product screenshots, no API docs, and no named customer logos, making it hard to verify product maturity independently.
OverallB Tier
The $10M ARR LOI is the headline — if real and converts, this is a serious company. But an LOI is not revenue, and the near-empty website gives no corroboration of a working product. The founding team has genuine domain relevance (dentist + AI/medical imaging engineer) but no prior exits and limited senior industry experience. FDA 510(k) pursuit is a double-edged sword: moat if cleared, 18-month+ distraction if not. The orthopedic surgical planning market is real and large with enterprise buyers, but Mango needs to close that LOI into actual ARR and show a working product to move up a tier.
Active Founders
